Polypid Ltd (PYPD)

$3.50 +0.04 (1.16%)
Market Cap 55.64M
Revenue (ttm) 0.00
Net Income (ttm) -29.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.32
Volume 66,600
Avg Vol 59,268
Day's Range N/A - N/A
Shares Out 15.90M
Stochastic %K 78%
Beta 1.50
Analysts Strong Sell
Price Target $12.50

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
NVDAMillionaire
NVDAMillionaire Oct. 2 at 6:15 AM
$PYPD Great piece that accurately captures PYPD's current position. So if you want to refresh your understanding of PYPD or learn about PYPD for the first time, this is essential reading. https://beyondspx.com/quote/PYPD/analysis/polypid-s-d-plex100-a-breakthrough-in-surgical-infection-prevention-poised-for-market-entry-pypd
0 · Reply
BenGang
BenGang Oct. 1 at 3:12 PM
$PYPD
0 · Reply
WallStWireAds
WallStWireAds Sep. 30 at 4:36 PM
$PYPD https://stocktwits.com/symbol/PYPD/companycall
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 1:17 PM
$PYPD 08:50 on Sep. 30 2025 PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Sep. 30 at 12:47 PM
$PYPD https://caplynx.io/9A7bWjm
0 · Reply
PaulWalter
PaulWalter Sep. 29 at 9:41 PM
$PYPD Tumblweeds.
0 · Reply
WallStWireAds
WallStWireAds Sep. 21 at 7:24 PM
$PYPD https://capnotes.beehiiv.com/p/as-polypid-advances-towards-commercialization-recent-300m-m-a-activity-highlights-growing-value-of-h?li_fat_id=e2c6d6ec-41fb-4261-a410-180e10907070
1 · Reply
Project_Profit
Project_Profit Sep. 19 at 10:46 AM
$PYPD something is cooking here. Up in the premarket... This never trades in the PM session And up after yesterday's move higher. If they would announce a partnership, $10+ here. Go ahead, do it please.
0 · Reply
WallStWireAds
WallStWireAds Sep. 17 at 12:46 PM
$PYPD https://caplynx.io/1ZusfUu
0 · Reply
sxpl
sxpl Sep. 16 at 4:20 PM
$BABA $PDD $PYPD 🎯🤝
0 · Reply
Latest News on PYPD
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 4 days ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 17 days ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 18 days ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 4 weeks ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 4 weeks ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:52 PM EDT - 7 weeks ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 7 weeks ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 7 weeks ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 2 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 2 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 3 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 4 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 4 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 4 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 4 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 4 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 4 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 4 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:24 PM EDT - 5 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 5 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 5 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 5 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 7 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 7 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:44 AM EST - 8 months ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 8 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 8 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 8 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Dec 26, 2024, 10:31 AM EST - 10 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 10 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 10 months ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 11 months ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:06 PM EST - 11 months ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 11 months ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 9, 2024, 10:38 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

PolyPid to Participate in Citizens JMP Life Sciences Conference

May 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Apr 30, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Apr 24, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 28, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 11:13 AM EST - 1 year ago

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

NVDAMillionaire
NVDAMillionaire Oct. 2 at 6:15 AM
$PYPD Great piece that accurately captures PYPD's current position. So if you want to refresh your understanding of PYPD or learn about PYPD for the first time, this is essential reading. https://beyondspx.com/quote/PYPD/analysis/polypid-s-d-plex100-a-breakthrough-in-surgical-infection-prevention-poised-for-market-entry-pypd
0 · Reply
BenGang
BenGang Oct. 1 at 3:12 PM
$PYPD
0 · Reply
WallStWireAds
WallStWireAds Sep. 30 at 4:36 PM
$PYPD https://stocktwits.com/symbol/PYPD/companycall
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 1:17 PM
$PYPD 08:50 on Sep. 30 2025 PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Sep. 30 at 12:47 PM
$PYPD https://caplynx.io/9A7bWjm
0 · Reply
PaulWalter
PaulWalter Sep. 29 at 9:41 PM
$PYPD Tumblweeds.
0 · Reply
WallStWireAds
WallStWireAds Sep. 21 at 7:24 PM
$PYPD https://capnotes.beehiiv.com/p/as-polypid-advances-towards-commercialization-recent-300m-m-a-activity-highlights-growing-value-of-h?li_fat_id=e2c6d6ec-41fb-4261-a410-180e10907070
1 · Reply
Project_Profit
Project_Profit Sep. 19 at 10:46 AM
$PYPD something is cooking here. Up in the premarket... This never trades in the PM session And up after yesterday's move higher. If they would announce a partnership, $10+ here. Go ahead, do it please.
0 · Reply
WallStWireAds
WallStWireAds Sep. 17 at 12:46 PM
$PYPD https://caplynx.io/1ZusfUu
0 · Reply
sxpl
sxpl Sep. 16 at 4:20 PM
$BABA $PDD $PYPD 🎯🤝
0 · Reply
WallStWireAds
WallStWireAds Sep. 16 at 12:32 PM
$PYPD https://caplynx.io/6dcuB69
1 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Sep. 5 at 5:26 AM
$PYPD Position here growing weekly.
0 · Reply
Project_Profit
Project_Profit Sep. 3 at 2:48 PM
$PYPD Under the radar until it's on the radar $XBI
0 · Reply
WallStWireAds
WallStWireAds Sep. 3 at 12:32 PM
$PYPD https://caplynx.io/1qOjDVd
0 · Reply
WallStWireAds
WallStWireAds Sep. 2 at 12:31 PM
$PYPD https://caplynx.io/DvSusVo
0 · Reply
haily_haily
haily_haily Sep. 2 at 10:35 AM
$PYPD what the fuck happened here
1 · Reply
Finanz
Finanz Aug. 29 at 9:40 PM
$PYPD https://www.youtube.com/watch?v=uF8VxpyLJX0
0 · Reply
alphawolftrading
alphawolftrading Aug. 29 at 8:22 PM
$PYPD https://youtu.be/uF8VxpyLJX0?si=dhReM0XRbXcbgoDO
1 · Reply
WallStWireAds
WallStWireAds Aug. 20 at 7:35 AM
$PYPD https://alphacatalyst.beehiiv.com/p/the-race-for-oral-glp-1-eli-lilly-s-diassppointing-trial-results-turn-the-spotlight-to-polypid-s-inn
1 · Reply
WallStWireAds
WallStWireAds Aug. 18 at 1:18 PM
$PYPD https://www.tipranks.com/news/company-announcements/polypid-reports-positive-phase-3-results-and-strengthens-leadership
0 · Reply
BenGang
BenGang Aug. 15 at 6:50 PM
$PYPD
0 · Reply
PaulWalter
PaulWalter Aug. 15 at 7:24 AM
$PYPD this just has so much going for it. Great late stage products and plenty of cash. Cant get any love. ESG / Israel thing? They need US partner asap.
0 · Reply